August 6, 2026

Summary of Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2027 (Three Months Ended June 30, 2026)

[Japanese GAAP]

Company name: NIHON TRIM CO., LTD. Listing: Tokyo Stock Exchange
Securities code: 6788 URL: https://www.nihon-trim.co.jp/
Representative: Norio Tahara, President
Contact: Yasuhiro Daikoku, Senior Managing Executive Officer and General Manager of Administration Division
Tel: +81-(0) 6-6456-4600
Scheduled date of dividend payment: –
Supplementary materials for financial results: Yes
Holding of financial results meeting: None

(All amounts are rounded down to the nearest million yen)

1. Consolidated Financial Results for the Three Months Ended June 30, 2026 (April 1, 2026 – June 30, 2026)

(1) Consolidated results of operations (Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Three months ended June 30, 2026	6,729	13.1	855	48.4	915	45.8	532	32.7
Three months ended June 30, 2025	5,949	9.0	576	(25.4)	627	(22.9)	401	(29.4)

Note: Comprehensive income (million yen) Three months ended June 30, 2026: 642 (up 109.6%)
Three months ended June 30, 2025: 306 (down 50.8%)

	Net income per share	Diluted net income per share
	Yen	Yen
Three months ended June 30, 2026	71.62	–
Three months ended June 30, 2025	52.40	–

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
As of Jun. 30, 2026	36,680	25,087	63.4	3,125.38
As of Mar. 31, 2026	36,067	25,481	65.8	3,193.56

Reference: Shareholders' equity (million yen) As of Jun. 30, 2026: 23,241 As of Mar. 31, 2026: 23,741

2. Dividends

	Dividend per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended Mar. 31, 2026	–	0.00	–	130.00	130.00
Fiscal year ending Mar. 31, 2027	–				
Fiscal year ending Mar. 31, 2027 (forecasts)		0.00	–	130.00	130.00

Note: Revisions to the most recently announced dividend forecast: None

3. Consolidated Forecast for the Fiscal Year Ending March 31, 2027 (April 1, 2026 - March 31, 2027)

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Net income per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	13,740	10.8	1,870	19.6	1,980	18.1	1,250	12.9	165.95
Full year	27,000	11.8	3,300	12.2	3,500	11.2	2,200	8.3	292.06

Note: Revisions to the most recently announced consolidated forecast: None

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

Newly added: –   Excluded: –

(2) Application of special accounting methods for presenting quarterly consolidated financial statements: None

(3) Changes in accounting policies and accounting estimates, and restatements

(i) Changes in accounting policies due to revisions in accounting standards, others: None

(ii) Changes in accounting policies other than (i) above: None

(iii) Changes in accounting estimates: None

(iv) Restatements: None

(4) Number of outstanding shares (common shares)

(i) Number of shares issued at end of period (including treasury shares)

As of Jun. 30, 2026:	8,656,780 shares
As of Mar. 31, 2026:	8,656,780 shares

(ii) Number of treasury shares at end of period

As of Jun. 30, 2026:	1,220,290 shares
As of Mar. 31, 2026:	1,222,590 shares

(iii) Average number of shares outstanding during the period

Three months ended Jun. 30, 2026:	7,435,076 shares
Three months ended Jun. 30, 2025:	7,656,081 shares

Note: The Company has adopted the Employee Stock Ownership Plan (J-ESOP) and the Trust-Type Employee Shareholding Incentive Plan (E-Ship). The company shares held by these trusts are included in the number of treasury shares, which are to be deducted from the calculation of the number of treasury shares at end of period and the average number of shares outstanding during the period.

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Cautionary statement with respect to forward-looking statements, and other special items

Earnings forecasts regarding future performance in this material are based on assumptions judged to be valid and information currently available to the Company, and the Company does not in any way guarantee the achievement of the forecasts. Actual results may differ significantly from these forecasts for a number of factors. Please refer to “1. Overview of Results of Operations, etc., (3) Explanation of the Future Outlook, including Consolidated Performance Forecasts” on page 3 of the attachments for assumptions for forecasts and notes of caution for usage.

Contents of Attachments

1. Overview of Results of Operations, etc.

(1) Overview of Results of Operations for the Period under Review

The Nihon Trim Group ("the Group") is committed to "contributing to the creation of healthy and comfortable lives" under its corporate philosophy. To this end, the Group operates its business under the main theme of health and medical care. The Group's mission is to contribute to people's well-being through its businesses including Electrolyzed Hydrogen Water (EHW), electrolyzed water hemodialysis, and regenerative medicine.

The Group's EHW apparatus is a controlled medical device that has been approved for its effects on **improvement of gastrointestinal conditions**, and its water purification cartridge installed in the device is equipped with a function to remove a total of 22 substances: 17 substances specified by JIS standards, together with five substances, including PFAS (generic name for organic fluorine compounds), specified by the voluntary standards of the Japan Water Purifier Association (JWPAS), thereby contributing to the creation of an environment where people can live in good health with peace of mind. In addition, applications of EHW are expected in a wide range of fields, including contribution to improving the QOL of hemodialysis patients in the medical field, and increases in crop yields and higher added value for crops in the agricultural field. Its possibilities are expanding further and further.

Under the slogan "Society will always need our products, at any point in time," the Group will contribute to the realization of a sustainable society and achieve sustainable enhancement of its corporate and shareholder value.

During the first three months of the current fiscal year, the Group's net sales increased 13.1% year on year to 6,729 million yen. In addition to solid sales of EHW apparatus and water purification cartridges, the bottled water business in Indonesia continued to maintain high growth, resulting in net sales reaching a record quarterly high.

Operating profit increased 48.4% to 855 million yen, ordinary profit increased 45.8% to 915 million yen, and profit attributable to owners of parent increased 32.7% to 532 million yen. Due to the increase in net sales, profits at all levels exceeded those of the same period of the previous fiscal year. On the other hand, in association with the rise in crude oil prices against the backdrop of factors such as heightened tensions in the Middle East, prices of resin materials continue to rise. In addition, as cost-increasing factors, including increased human resource investment and strengthened advertising and promotional activities, are expected to continue, we will seek further expansion of sales and thorough cost management, and strive to maintain and improve profitability.

For the first quarter of the current fiscal year, both net sales and profits at all levels are progressing steadily in line with the full-year plan.

Results by business segment were as follows.

Water Healthcare Business

In the EHW apparatus sales business, net sales increased 10.1% year on year to 2,604 million yen.

In the direct sales division, the DS Division, which primarily focuses on workplace sales, posted a 12.2% year-on-year increase in net sales. Sales channel development has progressed steadily in the sports and beauty care fields, financial institutions, and other areas, and the number of seminars held has increased. Going forward, we will proceed with the introduction of new sales tools and the expansion of sales personnel, and work to further expand sales.

In the wholesale and OEM division (MS Division), which covers indirect sales, we have continued our efforts to provide sales support to existing domestic agents, while focusing on acquiring new agents and expanding overseas transactions.

With regard to sales of water purification cartridges in Japan, which generate a consistent revenue stream once an EHW apparatus is installed, net sales increased 7.4% to 1,560 million yen, showing strong performance. We will continue to strengthen customer service, including regular information distribution and follow-up calls, aiming to maintain and expand a stable revenue base.

PT. SUPER WAHANA TEHNO, which operates a bottled water business in Indonesia, recorded net sales of 1,495 million yen (up 39.2% year on year). The business continues to maintain a high growth rate, driven by the strengthening of TV commercials, advertisements on social networking services, and various promotional measures aimed at expanding market share. In Indonesia, health awareness is steadily increasing, supported by higher income levels that have come with stable economic growth. As a leading company in the alkaline drinking water market, we will aim for further significant growth.

As a result of the above, the water healthcare business recorded net sales of 5,984 million yen (up 15.2% year on year), with segment profit of 786 million yen (up 43.5% year on year).

Medical Business

In the electrolyzed water hemodialysis (*1) business, the number of facilities that have adopted electrolyzed water hemodialysis has currently reached 37 facilities with 1,127 beds, and approximately 3,400 people are currently receiving treatments with electrolyzed water hemodialysis. Although there were no new introductions in the first quarter of the current fiscal year, eight presentations related to electrolyzed water hemodialysis were given at the 71st Annual Meeting of the Japanese Society for Dialysis Therapy held in June this year, and we have continued active information dissemination, with recognition steadily improving. Inquiries and specific business discussions triggered by this academic conference are also progressing, and we will continue to work on collecting evidence and dissemination activities.

(*1) Electrolyzed water hemodialysis offers a next-generation of new dialysis treatment using electrolyzed RO water containing dissolved hydrogen, which is produced by our technology, to dilute dialysate. It is the world's first technology that focuses attention on the functions of water as a solvent. We obtained data suggesting that electrolyzed water hemodialysis may reduce the dosage of drugs, the complication rate, and the annual crude death rate (CDR) compared to traditional hemodialysis, which has drawn attention.

In the field of regenerative medicine, StemCell Institute Inc. (listed on TSE Growth Market, Securities Code: 7096, our share: 71.2%) continues to perform steadily. The company published its earnings results for the three months ended June 30, 2026, on August 6 this year, the same date as did the Group. For details, please refer to the StemCell Institute's Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2027.

As a result of the above, the medical business recorded net sales of 745 million yen (down 1.0% year on year) with segment profit of 68 million yen (up 144.7% year on year).

(2) Overview of Financial Position for the Period under Review

Total assets increased 613 million yen, or 1.7%, from the end of the previous fiscal year to 36,680 million yen at the end of the first quarter of the current fiscal year on a consolidated basis. The main factors were increases in notes and accounts receivable-trade of 436 million yen, investment securities of 179 million yen, and finished goods of 100 million yen, despite a decrease in cash and deposits of 165 million yen.

Total liabilities increased 1,007 million yen, or 9.5%, from the end of the previous fiscal year to 11,593 million yen. The main factors were increases in accounts payable-trade of 311 million yen, accounts payable-other included in other under current liabilities of 414 million yen, short-term borrowings of 188 million yen and deposits received of 136 million yen, despite decreases in income taxes payable of 151 million yen and provision for bonuses of 124 million yen.

Net assets decreased 394 million yen, or 1.5%, from the end of the previous fiscal year to 25,087 million yen. The main factors were dividend payments of 1,044 million yen, which were partially offset by the recognition of profit attributable to owners of parent of 532 million yen and an increase in non-controlling interests of 105 million yen.

The Group continues to maintain virtually debt-free management, and with a strong financial base, we will work to sustainably enhance corporate value.

(3) Explanation of the Future Outlook, including Consolidated Performance Forecasts

There are no revisions to the full-year consolidated forecast for the fiscal year ending March 31, 2027, which was announced in the "Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2026," dated May 13, 2026.

2. Quarterly Consolidated Financial Statements and Notes

(1) Quarterly Consolidated Balance Sheet

(Thousands of yen)

	FY3/26 (As of Mar. 31, 2026)	First quarter of FY3/27 (As of Jun. 30, 2026)
Assets		
Current assets		
Cash and deposits	14,209,247	14,043,373
Notes and accounts receivable-trade	7,119,741	7,556,333
Finished goods	601,950	702,006
Raw materials and supplies	1,135,760	1,098,791
Other	317,492	312,996
Allowance for doubtful accounts	(28,859)	(29,182)
Total current assets	23,355,332	23,684,319
Non-current assets		
Property, plant and equipment		
Land	2,998,407	3,001,107
Other, net	2,033,050	2,045,796
Total property, plant and equipment	5,031,457	5,046,904
Intangible assets		
Goodwill	274,671	265,391
Other	327,311	288,846
Total intangible assets	601,983	554,237
Investments and other assets		
Investment securities	2,859,707	3,039,277
Long-term time deposits	1,500,000	1,500,000
Other	2,733,085	2,869,978
Allowance for doubtful accounts	(14,173)	(14,173)
Total investments and other assets	7,078,619	7,395,082
Total non-current assets	12,712,060	12,996,224
Total assets	36,067,392	36,680,544
Liabilities		
Current liabilities		
Accounts payable-trade	619,947	931,059
Income taxes payable	487,886	336,388
Advances received	4,443,644	4,504,573
Provision for bonuses	202,987	78,120
Provision for product warranties	92,000	92,000
Provision for share-based payments	–	83,186
Other	1,880,630	2,656,849
Total current liabilities	7,727,095	8,682,178
Non-current liabilities		
Long-term borrowings	1,011,161	995,579
Provision for share-based payments	276,357	216,879
Provision for retirement benefits for directors (and other officers)	293,901	302,356
Retirement benefit liability	422,802	431,112
Other	854,441	965,010
Total non-current liabilities	2,858,663	2,910,938
Total liabilities	10,585,759	11,593,117

(Thousands of yen)

	FY3/26 (As of Mar. 31, 2026)	First quarter of FY3/27 (As of Jun. 30, 2026)
Net assets		
Shareholders' equity		
Share capital	992,597	992,597
Capital surplus	1,807,969	1,807,969
Retained earnings	25,345,197	24,832,814
Treasury shares	(4,484,818)	(4,476,320)
Total shareholders' equity	23,660,945	23,157,060
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(23,243)	(26,705)
Foreign currency translation adjustment	92,394	101,113
Remeasurements of defined benefit plans	11,409	10,356
Total accumulated other comprehensive income	80,559	84,764
Non-controlling interests	1,740,128	1,845,601
Total net assets	25,481,633	25,087,427
Total liabilities and net assets	36,067,392	36,680,544

(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income

Quarterly Consolidated Statement of Income (For the Three-month Period)

(Thousands of yen)

	First three months of FY3/26 (Apr. 1, 2025 – Jun. 30, 2025)	First three months of FY3/27 (Apr. 1, 2026 – Jun. 30, 2026)
Net sales	5,949,878	6,729,820
Cost of sales	1,905,168	2,203,581
Gross profit	4,044,709	4,526,239
Selling, general and administrative expenses	3,468,315	3,670,872
Operating profit	576,394	855,367
Non-operating income		
Interest and dividend income	23,703	32,291
Rental income from real estate	21,004	21,004
Gain on sale of non-current assets	7,761	8,414
Other	7,162	6,038
Total non-operating income	59,631	67,748
Non-operating expenses		
Interest expenses	1,358	1,546
Share of loss of entities accounted for using equity method	664	499
Depreciation of assets for rent	3,485	3,485
Other	2,836	2,265
Total non-operating expenses	8,344	7,796
Ordinary profit	627,681	915,318
Extraordinary income		
Gain on sale of non-current assets	487	–
Total extraordinary income	487	–
Extraordinary losses		
Loss on valuation of investment securities	–	1,000
Total extraordinary losses	–	1,000
Profit before income taxes	628,169	914,318
Income taxes-current	220,136	283,669
Income taxes-deferred	(19,476)	(7,800)
Total income taxes	200,659	275,868
Profit	427,509	638,449
Profit attributable to non-controlling interests	26,299	105,958
Profit attributable to owners of parent	401,210	532,491

Quarterly Consolidated Statement of Comprehensive Income (For the Three-month Period)

(Thousands of yen)

	First three months of FY3/26 (Apr. 1, 2025 – Jun. 30, 2025)	First three months of FY3/27 (Apr. 1, 2026 – Jun. 30, 2026)
Profit	427,509	638,449
Other comprehensive income		
Valuation difference on available-for-sale securities	6,684	(4,860)
Foreign currency translation adjustment	(122,953)	9,654
Remeasurements of defined benefit plans, net of tax	(3,795)	(1,100)
Share of other comprehensive income of entities accounted for using equity method	(1,036)	25
Total other comprehensive income	(121,102)	3,719
Comprehensive income	306,407	642,169
Comprehensive income attributable to:		
Owners of parent	332,797	536,696
Non-controlling interests	(26,389)	105,473

(3) Notes to Quarterly Consolidated Financial Statements

Segment and Other Information

1. Overview of reportable segment

The Group’s reportable segment is a component for which discrete financial information is available and which is regularly reviewed by the Group’s highest decision-making body in order to determine management resources to be allocated to the segment and assess its performance.

There are two reportable operating segments: the water healthcare business and the medical business.

The water healthcare business includes EHW apparatus sales and associated operations, as well as bottled water sales. The medical business includes business operations in the fields of medical and regenerative medicine.

2. Information related to net sales and profit or loss of each reportable segment

I. First three months of FY3/26 (Apr. 1, 2025 – Jun. 30, 2025)

(Thousands of yen)

	Reportable segment			Adjustments	Amounts recorded in quarterly consolidated financial statement of income (Note)
	Water Healthcare	Medical	Subtotal		
Net sales					
Net sales to external customers	5,196,829	753,049	5,949,878	–	5,949,878
Inter-segment net sales and transfers	–	–	–	–	–
Total	5,196,829	753,049	5,949,878	–	5,949,878
Segment profit	548,269	28,125	576,394	–	576,394

Note: The segment profit subtotal is consistent with the operating profit of the quarterly consolidated statement of income.

II. First three months of FY3/27 (Apr. 1, 2026 – Jun. 30, 2026)

(Thousands of yen)

	Reportable segment			Adjustments	Amounts recorded in quarterly consolidated financial statement of income (Note)
	Water Healthcare	Medical	Subtotal		
Net sales					
Net sales to external customers	5,984,294	745,526	6,729,820	–	6,729,820
Inter-segment net sales and transfers	–	–	–	–	–
Total	5,984,294	745,526	6,729,820	–	6,729,820
Segment profit	786,556	68,810	855,367	–	855,367

Note: The segment profit subtotal is consistent with the operating profit of the quarterly consolidated statement of income.

Significant Changes in Shareholders’ Equity

Not applicable.

Assumption for Going Concern

Not applicable.

Statement of Cash Flows

Quarterly consolidated statement of cash flows for the first three months of the current fiscal year has not been prepared. Depreciation (including depreciation related to intangible assets excluding goodwill) and amortization of goodwill for the first three months ended June 30, 2025 and the first three months ended June 30, 2026 are as follows.

	First three months of FY3/26 (Apr. 1, 2025 - Jun. 30, 2025)	First three months of FY3/27 (Apr. 1, 2026 - Jun. 30, 2026)
Depreciation	73,101 thousand yen	133,014 thousand yen
Amortization of goodwill	9,279 thousand yen	9,279 thousand yen